About Skye Bioscience
Skye Bioscience is a company based in San Diego (United States) founded in 2011.. Skye Bioscience has raised $3.82 million across 20 funding rounds from investors including Driehaus, Hilco Vision and 5AM Ventures. The company has 16 employees as of December 31, 2024. Skye Bioscience has completed 1 acquisition, including Bird Rock Bio. Skye Bioscience offers products and services including Nimacimab. Skye Bioscience operates in a competitive market with competitors including GW Pharma, IGC Pharma, MIRA Pharmaceuticals, NEUROPATHIX and Agrithera, among others.
- Headquarter San Diego, United States
- Employees 16 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Skye Bioscience, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-26.57 M29.43as on Dec 31, 2024
-
EBITDA
$-36.13 M-166.68as on Dec 31, 2024
-
Total Equity Funding
$3.82 M (USD)
in 20 rounds
-
Latest Funding Round
$40 M (USD), Post-IPO
Mar 13, 2024
-
Investors
Driehaus
& 6 more
-
Employee Count
16
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Skye Bioscience
Skye Bioscience is a publicly listed company on the NASDAQ with ticker symbol SKYE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Skye Bioscience
Skye Bioscience offers a comprehensive portfolio of products and services, including Nimacimab. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibits CB1 receptor to aid obesity and metabolic management
Unlock access to complete
Unlock access to complete
Funding Insights of Skye Bioscience
Skye Bioscience has successfully raised a total of $3.82M across 20 strategic funding rounds. The most recent funding activity was a Post-IPO round of $40 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 20
- Last Round Post-IPO — $40.0M
- First Round First Round
- Investors Count 7
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2024 | Amount | Post-IPO - Skye Bioscience | Valuation |
investors |
|
| Jan, 2024 | Amount | Post-IPO - Skye Bioscience | Valuation |
investors |
|
| Nov, 2018 | Amount | Post-IPO - Skye Bioscience | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Skye Bioscience
Skye Bioscience has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Driehaus, Hilco Vision and 5AM Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed incubator focused on the healthcare startups
|
Founded Year | Domain | Location | |
|
Private equity and hedge fund investments in healthcare are managed.
|
Founded Year | Domain | Location | |
|
Long-term investments in healthcare companies are managed by Altium Capital.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Skye Bioscience
Skye Bioscience has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Bird Rock Bio. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Antibody therapeutics targeting G-Protein Coupled Receptors are developed and validated.
|
2008 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Skye Bioscience
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Skye Bioscience Comparisons
Competitors of Skye Bioscience
Skye Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GW Pharma, IGC Pharma, MIRA Pharmaceuticals, NEUROPATHIX and Agrithera, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of cannabinoid medicines for MS spasticity, cancer pain and childhood epilepsy
|
|
| domain | founded_year | HQ Location |
Pharmaceutical products targeting neurological disorders like Alzheimer's are developed.
|
|
| domain | founded_year | HQ Location |
Cannabinoid-based therapeutics for chronic pain and anxiety are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics targeting inflammation, neurodegeneration, oxidative stress, and neuropathic pain
|
|
| domain | founded_year | HQ Location |
Cannabis-based therapeutics are developed for pain and neurological disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Skye Bioscience
Frequently Asked Questions about Skye Bioscience
When was Skye Bioscience founded?
Skye Bioscience was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Where is Skye Bioscience located?
Skye Bioscience is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Skye Bioscience?
Punit Dhillon is the current CEO of Skye Bioscience.
Is Skye Bioscience a funded company?
Skye Bioscience is a funded company, having raised a total of $3.82M across 20 funding rounds to date. The company's 1st funding round was a Post-IPO of $2M, raised on Nov 06, 2012.
How many employees does Skye Bioscience have?
As of Dec 31, 2024, the latest employee count at Skye Bioscience is 16.
What does Skye Bioscience do?
Founded in 2011 and based in San Diego, United States, cannabinoid-based therapies targeting the endocannabinoid system are developed by the company for glaucoma, ocular hypertension, and additional diseases. Operations focus on pharmaceutical candidates such as THCVHS, a prodrug of tetrahydrocannabinol formulated for topical ocular use, and CBDVHS, an analog of cannabidiol with various therapeutic potentials. The biotech sector is served through these endocannabinoid-modulating treatments.
Who are the top competitors of Skye Bioscience?
Skye Bioscience's top competitors include IGC Pharma, MIRA Pharmaceuticals and GW Pharma.
What products or services does Skye Bioscience offer?
Skye Bioscience offers Nimacimab.
Is Skye Bioscience publicly traded?
Yes, Skye Bioscience is publicly traded on NASDAQ under the ticker symbol SKYE.
How many acquisitions has Skye Bioscience made?
Skye Bioscience has made 1 acquisition, including Bird Rock Bio.
Who are Skye Bioscience's investors?
Skye Bioscience has 7 investors. Key investors include Driehaus, Hilco Vision, 5AM Ventures, Ally Bridge Group, and Sphera Fund.
What is Skye Bioscience's ticker symbol?
The ticker symbol of Skye Bioscience is SKYE on NASDAQ.